| pubmed-article:17686100 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17686100 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:17686100 | lifeskim:mentions | umls-concept:C0008976 | lld:lifeskim |
| pubmed-article:17686100 | lifeskim:mentions | umls-concept:C0003364 | lld:lifeskim |
| pubmed-article:17686100 | lifeskim:mentions | umls-concept:C0005823 | lld:lifeskim |
| pubmed-article:17686100 | lifeskim:mentions | umls-concept:C2584321 | lld:lifeskim |
| pubmed-article:17686100 | lifeskim:mentions | umls-concept:C0686904 | lld:lifeskim |
| pubmed-article:17686100 | lifeskim:mentions | umls-concept:C0032893 | lld:lifeskim |
| pubmed-article:17686100 | lifeskim:mentions | umls-concept:C0205210 | lld:lifeskim |
| pubmed-article:17686100 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:17686100 | lifeskim:mentions | umls-concept:C1521840 | lld:lifeskim |
| pubmed-article:17686100 | pubmed:issue | 9 | lld:pubmed |
| pubmed-article:17686100 | pubmed:dateCreated | 2007-8-9 | lld:pubmed |
| pubmed-article:17686100 | pubmed:abstractText | Pharmacological treatment of hypertension represents a cost-effective way for preventing cardiovascular and renal complications. To benefit maximally from antihypertensive treatment blood pressure (BP) should be brought to below 140/90 mmHg in every hypertensive patient, and even lower (< 130/80 mmHg) if diabetes or renal disease co-exists. Most of the time such targets cannot be reached using monotherapies. This is especially true in patients who exhibit a high cardiovascular risk. The co-administration of two agents acting by different mechanisms considerably increases BP control. Such preparations are not only efficacious, but also well tolerated, and some fixed low-dose combinations have a tolerability profile similar to placebo. This is for instance the case for the preparation containing the angiotensin-converting enzyme inhibitor perindopril (2 mg) and the diuretic indapamide (0.625 mg), a fixed low-dose combination that has recently been shown in controlled interventional trials to be more effective than monotherapies in reducing albuminuria, regressing cardiac hypertrophy and improving macrovascular stiffness. Fixed-dose combinations are becoming more and more popular and are even proposed by current hypertension guidelines as a first-line option to treat hypertensive patients. | lld:pubmed |
| pubmed-article:17686100 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17686100 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17686100 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17686100 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17686100 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17686100 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17686100 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17686100 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17686100 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:17686100 | pubmed:issn | 1368-5031 | lld:pubmed |
| pubmed-article:17686100 | pubmed:author | pubmed-author:LaurentSS | lld:pubmed |
| pubmed-article:17686100 | pubmed:author | pubmed-author:HolzgreveHH | lld:pubmed |
| pubmed-article:17686100 | pubmed:author | pubmed-author:WaeberBB | lld:pubmed |
| pubmed-article:17686100 | pubmed:author | pubmed-author:ManciaGG | lld:pubmed |
| pubmed-article:17686100 | pubmed:author | pubmed-author:AmbrosioniEE | lld:pubmed |
| pubmed-article:17686100 | pubmed:author | pubmed-author:RuilopeL MLM | lld:pubmed |
| pubmed-article:17686100 | pubmed:author | pubmed-author:Struijker-Bou... | lld:pubmed |
| pubmed-article:17686100 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17686100 | pubmed:volume | 61 | lld:pubmed |
| pubmed-article:17686100 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17686100 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17686100 | pubmed:pagination | 1592-602 | lld:pubmed |
| pubmed-article:17686100 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:17686100 | pubmed:meshHeading | pubmed-meshheading:17686100... | lld:pubmed |
| pubmed-article:17686100 | pubmed:meshHeading | pubmed-meshheading:17686100... | lld:pubmed |
| pubmed-article:17686100 | pubmed:meshHeading | pubmed-meshheading:17686100... | lld:pubmed |
| pubmed-article:17686100 | pubmed:meshHeading | pubmed-meshheading:17686100... | lld:pubmed |
| pubmed-article:17686100 | pubmed:meshHeading | pubmed-meshheading:17686100... | lld:pubmed |
| pubmed-article:17686100 | pubmed:meshHeading | pubmed-meshheading:17686100... | lld:pubmed |
| pubmed-article:17686100 | pubmed:meshHeading | pubmed-meshheading:17686100... | lld:pubmed |
| pubmed-article:17686100 | pubmed:meshHeading | pubmed-meshheading:17686100... | lld:pubmed |
| pubmed-article:17686100 | pubmed:meshHeading | pubmed-meshheading:17686100... | lld:pubmed |
| pubmed-article:17686100 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17686100 | pubmed:articleTitle | The need for combination antihypertensive therapy to reach target blood pressures: what has been learned from clinical practice and morbidity-mortality trials? | lld:pubmed |
| pubmed-article:17686100 | pubmed:affiliation | Department of Pharmacology and Toxicology, University of Maastricht, MD Maastricht, The Netherlands. h.struijkerboudier@farmaco.unimaas.nl | lld:pubmed |
| pubmed-article:17686100 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17686100 | pubmed:publicationType | Review | lld:pubmed |
